CN104768952A - PI3Kδ抑制剂 - Google Patents

PI3Kδ抑制剂 Download PDF

Info

Publication number
CN104768952A
CN104768952A CN201380041007.1A CN201380041007A CN104768952A CN 104768952 A CN104768952 A CN 104768952A CN 201380041007 A CN201380041007 A CN 201380041007A CN 104768952 A CN104768952 A CN 104768952A
Authority
CN
China
Prior art keywords
bases
mmol
protective embankment
base
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380041007.1A
Other languages
English (en)
Other versions
CN104768952B (zh
Inventor
李丽
张艳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KBP Biosciences Co Ltd
Original Assignee
KBP Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KBP Biosciences Co Ltd filed Critical KBP Biosciences Co Ltd
Priority to CN201380041007.1A priority Critical patent/CN104768952B/zh
Publication of CN104768952A publication Critical patent/CN104768952A/zh
Application granted granted Critical
Publication of CN104768952B publication Critical patent/CN104768952B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

通式(Ⅰ)所示的PI3Kδ抑制剂化合物、其药学上可接受的盐类、立体异构体或氘代物，这些化合物的制备方法、含有这些化合物的药物制剂，以及这些化合物在制备治疗炎性疾病或肿瘤的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380041007.1A 2012-08-08 2013-08-08 PI3Kδ抑制剂 Active CN104768952B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380041007.1A CN104768952B (zh) 2012-08-08 2013-08-08 PI3Kδ抑制剂

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN201210279961 2012-08-08
CN2012102799611 2012-08-08
CN201210529334 2012-12-10
CN2012105293349 2012-12-10
CN201310130010 2013-04-16
CN2013101300102 2013-04-16
CN201380041007.1A CN104768952B (zh) 2012-08-08 2013-08-08 PI3Kδ抑制剂
PCT/CN2013/000934 WO2014023083A1 (zh) 2012-08-08 2013-08-08 PI3Kδ抑制剂

Publications (2)

Publication Number Publication Date
CN104768952A true CN104768952A (zh) 2015-07-08
CN104768952B CN104768952B (zh) 2016-10-19

Family

ID=50067418

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041007.1A Active CN104768952B (zh) 2012-08-08 2013-08-08 PI3Kδ抑制剂

Country Status (3)

Country Link
CN (1) CN104768952B (zh)
SG (2) SG10202003090VA (zh)
WO (1) WO2014023083A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304600A (zh) * 2022-09-29 2022-11-08 北京鑫开元医药科技有限公司 mTOR抑制剂、制备方法及用途

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
SG11201600028YA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
SG11201604825VA (en) 2013-12-20 2016-07-28 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
ES2833025T3 (es) * 2014-06-13 2021-06-14 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa
NZ726055A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016016528A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
KR20170012560A (ko) * 2014-06-13 2017-02-02 길리애드 사이언시즈, 인코포레이티드 포스파티딜이노시톨 3-키나제 억제제
KR20170082490A (ko) 2014-07-04 2017-07-14 루핀 리미티드 Pi3k 억제제로서 퀴놀리지논 유도체
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101932146B1 (ko) * 2016-07-14 2018-12-24 주식회사 바이오웨이 Pi3k를 억제하는 신규한 퀴나졸리논 유도체 및 이를 포함하는 약학적 조성물
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN108003190B (zh) * 2017-12-27 2020-06-12 东南大学 一种草铵膦的制备方法
JP7450541B2 (ja) 2018-01-20 2024-03-15 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換アミノピリミジン化合物及び使用方法
CN110283174B (zh) * 2019-07-31 2021-07-23 安徽中医药大学 一类PI3Kδ抑制剂及其用途
CN111440173B (zh) * 2020-03-27 2021-05-14 山东大学 一种pi3k抑制剂的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031569A (zh) * 2004-05-13 2007-09-05 艾科斯有限公司 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN101965335A (zh) * 2008-01-04 2011-02-02 英特利凯恩股份有限公司 某些化学实体、组合物和方法
CN102838601A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010618A (es) * 2000-04-25 2004-05-05 Icos Corp Inhibidores de fosfatidilinositol 3-quinasa delta.
CA2569406A1 (en) * 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
GEP20125635B (en) * 2007-11-13 2012-09-10 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101031569A (zh) * 2004-05-13 2007-09-05 艾科斯有限公司 作为人磷脂酰肌醇3－激酶δ抑制剂的喹唑啉酮
CN101965335A (zh) * 2008-01-04 2011-02-02 英特利凯恩股份有限公司 某些化学实体、组合物和方法
CN102838601A (zh) * 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304600A (zh) * 2022-09-29 2022-11-08 北京鑫开元医药科技有限公司 mTOR抑制剂、制备方法及用途
CN115304600B (zh) * 2022-09-29 2023-01-13 北京鑫开元医药科技有限公司 mTOR抑制剂、制备方法及用途

Also Published As

Publication number Publication date
SG10202003090VA (en) 2020-05-28
SG11201501173SA (en) 2015-05-28
CN104768952B (zh) 2016-10-19
WO2014023083A1 (zh) 2014-02-13

Similar Documents

Publication Publication Date Title
CN104768952A (zh) PI3Kδ抑制剂
CA3023154C (en) Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
TWI763722B (zh) Tyk2抑制劑及其用途
TWI525093B (zh) 用作為３'磷酸肌醇依賴性激酶１（ｐｄｋ１）抑制劑之雜環化合物
TWI527800B (zh) 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
EP2004653B1 (en) 3-substituted n-(aryl- or heteroaryl)-pyrazo[1,5-a]pyrimidines as kinase inhibitors
CN104968664A (zh) 作为酪氨酸激酶抑制剂的并环化合物
WO2014149164A1 (en) Mk2 inhibitors and uses thereof
CA3126034A1 (en) Tyk2 inhibitors and uses thereof
KR20140040774A (ko) 이미다조피리딘 화합물
EA019027B1 (ru) Производные флуорена, содержащие их композиции и применение
SK4322003A3 (en) Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
AU2015320142B2 (en) Novel imidazopyridazine compounds and their use
JP2012505874A (ja) タンパク質キナーゼとしての複素環化合物
KR20150092279A (ko) 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
CA2905751A1 (en) Novel compounds and compositions for inhibition of fasn
WO2020125759A1 (zh) 作为wnt信号通路抑制剂的化合物及其医学应用
AU2019319835A1 (en) Indole and azaindole inhibitors of PAD enzymes
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
CN117957219A (zh) 一种吡啶类衍生物及其用途
US9126935B2 (en) Aurora kinase modulators and methods of use
CN117105936A (zh) 一种作为FLT3抑制剂的咪唑并[1,2－a]吡啶化合物及其制备方法和用途
US20090118277A1 (en) 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors
WO2023244430A1 (en) Pyrimidine amide compounds and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 250101 Shandong city of Ji'nan province high tech Zone Hong Xing three North Road No. 2 building 401 Ji'nan trough

Applicant after: Shandong Henry Medical Science and Technology Co., Ltd.

Address before: Shandong province China Ji'nan City hi tech Development Zone, No. 750 Hua Road University Science Park B302

Applicant before: Shandong Henry Medical Science and Technology Co., Ltd.

COR Change of bibliographic data
C14 Grant of patent or utility model
GR01 Patent grant